Cardiomyocytes from human pluripotent stem cells (hPSCs) have the ability to advance specificity of in vitro assays for drug discovery and safety pharmacology. They may also provide a superior cell source for envisioned cell therapies to repair damaged hearts. All applications will require the production of cardiomyocytes (CMs) by robust upscalable bioprocesses via industry-compliant technologies. This paper describes a detailed procedure for producing hPSC-CMs in stirred tank bioreactors in 100 ml process scale. The strategy combines both hPSC expansion in suspension culture and, directly followed by, cardiogenic differentiation using small molecule-Wnt pathway modulators. We also provide a protocol describing how to plan and expand the pluripotent stem cells to enable parallel inoculation of 4× 150 ml parallel bioreactor differentiations, potentially producing more than 240 × 106 cardiomyocytes in 22 days.
CITATION STYLE
Halloin, C., Coffee, M., Manstein, F., & Zweigerdt, R. (2019). Production of cardiomyocytes from human pluripotent stem cells by bioreactor technologies. In Methods in Molecular Biology (Vol. 1994, pp. 55–70). Humana Press Inc. https://doi.org/10.1007/978-1-4939-9477-9_5
Mendeley helps you to discover research relevant for your work.